Drug Approval | October 29, 2021
Boehringer Ingelheim announces EMA marketing authorisation for spesolimab
Generalized pustular psoriasis is characterized by episodes of widespread eruptions of painful, sterile pustules
Generalized pustular psoriasis is characterized by episodes of widespread eruptions of painful, sterile pustules
The Phase 3 study is designed to bridge data collected from the vaccine efficacy trial conducted in India to the U.S. population
Moderate-to-severe plaque psoriasis affects about 35 per cent of patients. A key challenge is that many treatments stop working overtime and symptoms return
The company is continuing with the evaluation of canakinumab in lung cancer, and is applying findings to the overall lung cancer development plan
Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option
Incidences of Non-alcoholic Fatty Liver Disease (NAFLD) have been rising exponentially worldwide and are associated with co-morbidities including obesity, diabetes, hypertension and metabolic disorders
The interim analysis showed that the MVC-COV1901 vaccine has a good safety profile and elicits promising neutralising antibody titres
AZD7442 reduced risk of developing severe Covid-19 or death in Tackle Phase III outpatient treatment trial
If authorized, molnupiravir could be the first oral antiviral medicine for the treatment of Covid-19
Gantenerumab is an investigational antibody in Phase III development for early Alzheimer's disease (AD) and a comprehensive data set with an expected readout in mid-2022
Subscribe To Our Newsletter & Stay Updated
